Neuroblastoma Cancer Market

Neuroblastoma Cancer Market by Diagnostics (MIBG Scan, Imaging, Urine Analysis, Biopsy), Treatment (Surgery, Chemotherapy, Radiation therapy, Stem Cell Transplant, Immunotherapy), Staging, Pipeline, Regulatory, Reimbursement - Global Forecast to 2021

Report Code: UC 1730 Sep, 2020, by marketsandmarkets.com
COVID-19

Get in-depth analysis of the COVID-19 impact on the Neuroblastoma Cancer Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Neuroblastoma Cancer Market

Request For Special Pricing

Neuroblastoma is a rare extracranial solid tumor cancer that develops from immature nerve cells found in several areas of the body. It is the most common extracranial solid tumor in childhood. Tests and procedures used to diagnose neuroblastoma include: physical exam, urine and blood tests, imaging tests, removing a sample of tissue for testing, and removing a sample of bone marrow for testing.  Treatment options include: surgery, chemotherapy, radiation therapy, stem cell transplant, and immunotherapy. Newer treatments include newer form of radiation therapy that may help control high-risk neuroblastoma. The treatment uses a radioactive form of the chemical metaiodobenzylguanidine (MIBG). When injected in to the bloodstream, the MIBG travels to the neuroblastoma cells and releases the radiation. MIBG therapy is sometimes combined with chemotherapy or stem cell transplant.

Table of Contents

1 Introduction
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Geographic Scope
           1.3.3 Years Considered in the Study
    1.4 Limitations
    1.5 Market Stakeholders

2 Research Methodology
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Key Industry Insights
                    2.1.2.3 Breakdown of Primaries
    2.2 Market Size Estimation
    2.3 Market Breakdown and Data Triangulation
    2.4 Research Assumptions

3 Executive Summary

4 Premium Insights

5 Market Overview
    5.1 Introduction
    5.2 Market Segmentation
    5.3 Market Evolution
    5.4 Market Dynamics
           5.4.1 Key Market Drivers
           5.4.2 Key Market Restraints
           5.4.3 Key Market Opportunities
           5.4.4 Key Market Challenges

6 Industry Insights
    6.1 Introduction
    6.2 Epidemiology Coverage
    6.3 Pricing and Reimbursement Analysis
    6.4 Treatment Protocols
    6.5 Key Products Expected to Be Launched in the Market 
    6.6 Ongoing Clinical Trials

7 Neuroblastoma Market Diagnostics
    7.1 Introduction
    7.2 Metaiodobenzylguanidine (MIBG) Scan
    7.3 Imaging of the Primary Tumor Mass
    7.4 Urine Catecholamine Metabolites
    7.5 Biopsy

8 Neuroblastoma Market, By Staging
    8.1 Introduction
    8.2 Stage I
    8.3 Stage IIA
    8.4 Stage IIB
    8.5 Stage III
    8.6 Stage IV
    8.7 Stage IVS (Special Category)

9 Neuroblastoma Market, By Treatment
    9.1 Introduction
    9.2 Surgery
    9.3 Chemotherapy
    9.4 Radiation Therapy
    9.5 Stem Cell Transplant
    9.6 Immunotherapy

10 Neuroblastoma Market, By Region
     10.1 Introduction
     10.2 North America
     10.3 Europe
     10.4 Asia-Pacific
     10.5 Rest of the World (RoW)

11 Competitive Landscape
     11.1 Introduction
     11.2 Market Share Analysis, By Key Players
     11.3 Competitive Scenario
     11.4 Recent Developments
             11.4.1 New Products Launches and Product Enhancements
             11.4.2 Agreement/Partnership/Collaboration
             11.4.3 Mergers and Acquisitions
             11.4.4 Geographic Expansions
             11.4.5 Other Developments

12 Company Profiles*

13 Appendix
     13.1 Insights From Industry Experts 
     13.2 Discussion Guide 
     13.3 Introducing RT: Real Time Market Intelligence 
     13.4 Available Customizations 
     13.5 Related Reports

*Will Cover Ten Leading Companies in the Market.
Details on Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.


Request for detailed methodology, assumptions & how numbers were triangulated.

Please share your problem/objectives in greater details so that our analyst can verify if they can solve your problem(s).
8 4 0 4 4  
  • Select all
  • News-Letters with latest Market insights
  • Information & discussion on the relevant new products and services
  • Information & discussion on Market insights and Market information
  • Information & discussion on our events and conferences
    • Select all
    • Email Phone Professional and social network (Linkedin, etc)
Report Code
UC 1730
Available for Pre-Book
Choose License Type
Prebook Now
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Neuroblastoma Cancer Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home